Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have been given an average rating of “Moderate Buy” by the ten ratings firms that are presently covering the stock, MarketBeat reports. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $61.11.

Several research analysts have weighed in on HALO shares. HC Wainwright reissued a “buy” rating and set a $68.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday, December 18th. Piper Sandler lifted their price target on Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a research note on Monday, November 4th. Wells Fargo & Company lowered Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their price objective for the company from $58.00 to $62.00 in a report on Monday, October 7th. Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Finally, JPMorgan Chase & Co. lowered Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their price target for the company from $52.00 to $57.00 in a research report on Thursday, September 19th.

Insider Activity

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $53.26, for a total value of $532,600.00. Following the transaction, the senior vice president now owns 173,756 shares in the company, valued at approximately $9,254,244.56. The trade was a 5.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 2.70% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

Large investors have recently modified their holdings of the stock. Geode Capital Management LLC raised its position in shares of Halozyme Therapeutics by 1.0% during the third quarter. Geode Capital Management LLC now owns 3,060,131 shares of the biopharmaceutical company’s stock worth $175,194,000 after purchasing an additional 30,901 shares during the period. Congress Asset Management Co. lifted its stake in Halozyme Therapeutics by 446.5% during the third quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock valued at $139,298,000 after buying an additional 1,988,238 shares in the last quarter. Handelsbanken Fonder AB boosted its holdings in shares of Halozyme Therapeutics by 76.9% in the third quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock worth $112,715,000 after buying an additional 856,200 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Halozyme Therapeutics by 12.4% in the second quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company’s stock worth $99,363,000 after acquiring an additional 209,530 shares in the last quarter. Finally, American Century Companies Inc. increased its position in shares of Halozyme Therapeutics by 9.7% in the second quarter. American Century Companies Inc. now owns 821,266 shares of the biopharmaceutical company’s stock worth $43,002,000 after acquiring an additional 72,544 shares in the last quarter. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock opened at $47.54 on Thursday. Halozyme Therapeutics has a 52 week low of $33.15 and a 52 week high of $65.53. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. The stock has a market cap of $6.05 billion, a P/E ratio of 15.74, a price-to-earnings-growth ratio of 0.43 and a beta of 1.23. The stock has a 50 day moving average of $50.65 and a 200-day moving average of $54.13.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.